CDCN
@CureCastleman
Followers
1K
Following
478
Statuses
912
Castleman Disease Collaborative Network: turning promising research into permanent cures. Donate today at https://t.co/2Y2h2XN0uN
Joined July 2014
RT @AAMCtoday: As a med student, @DavidFajgenbaum nearly died several times from Castleman’s disease, a rare condition with no known treatm…
0
9
0
The new @WHO Classification of Haematolymphoid Tumours includes a section on Castleman disease for the first time ever thanks to the CDCN SAB's Amy Chadburn, David Fajgenbaum, and Megan Lim! Explore this resource on diagnosing and treating CD here:
0
0
0
RT @DavidFajgenbaum: What does Nobel Prize Winner Dr. Drew Weissman think of drug repurposing? Like us, he thinks it’s a no brainer! Deve…
0
14
0
I’m going to have an identity crisis! Should I be the LeCount Disease Collaborative Network?!
…but a recent paper came out indicating that Dr. Edwin LeCount may have actually first described it in 1899! Should it be called LeCount’s disease?!?
0
1
4
We love #drugrepurposing for #castleman disease, but this is our favorite one…
Really exciting to see this study reporting the effectiveness of sirolimus in a large cohort of idiopathic multicentric castleman disease patient! I discovered sirolimus could be a treatment for iMCD in 2014 and began testing it on myself…
0
0
3
RT @SALASeries: On our continued to-do list: support @DavidFajgenbaum and @EveryCure as they help alleviate suffering for the 300M people g…
0
3
0
In this study, researchers at the Center for Cytokine Storm Treatment & Laboratory (CSTL) at Penn shed light on the burden faced by patients with idiopathic multicentric Castleman disease (IMCD) at diagnosis and long-term.
0
0
1
Researchers at the Cytokine Storm Treatment & Laboratory (CSTL) share insights into idiopathic multicentric Castleman disease (iMCD) and its subtypes that could potentially lead to patients benefiting from more personalized, tailored treatments.
0
0
1
RT @thephilacitizen: From block captains to corporate leaders, we are privileged to have celebrated the diverse changemakers honored at The…
0
4
0
RT @DavidFajgenbaum: Thinking back 13 years ago when I was fighting for my life in the ICU, I thought that there was no chance that I would…
0
8
0
RT @EricTopol: My top 10 books for 2023 @abe_verghese @peteratmsr @mustafasuleyman @DoctorChrisVT @PeterAttiaMD @kkariko @drfeifei @PeterHo…
0
161
0
RT @DavidFajgenbaum: Great to see our collaborative work/discovery between @EveryCure, @Penn, and @CureCastleman selected as one of the top…
0
7
0
Love seeing this profile on @LinkedInNews about our co-founder, @DavidFajgenbaum!
I am beyond honored to be featured in @LinkedInNews Catalyst Series that highlights our journey #ChasingMyCure, the power of #horizontalthinking, and the amazing work my teams are doing at @EveryCure , @CureCastleman, @PennMedicine
0
0
2
RT @DavidFajgenbaum: So great to be at the @ASH_hematology annual meeting where we’re holding our annual @CureCastleman workshop and our t…
0
4
0
RT @DavidFajgenbaum: So good to see @doctorpemm at @ASH_hematology! Can’t wait for our annual #castleman meeting tonight! #castlemanwarrio…
0
3
0
RT @DavidFajgenbaum: New drug development is like starting at your own 1-yard line with a 10% chance of driving down the field to score big…
0
7
0
RT @DavidFajgenbaum: My passion for finding new uses for existing drugs started long before #chasingmycure While my mom was battling brain…
0
4
0
RT @DavidFajgenbaum: Thank you to @AJMC_Journal for featuring @EveryCure, in its latest documentary about rare disease treatment gaps! A…
0
5
0
RT @DavidFajgenbaum: Ancient drug reduces heart attacks? In this clip from the @Medscape Podcast, Dr. @EricTopol and I discuss Colchicin…
0
14
0